NY-IFF
3.1.2022 22:17:13 CET | Business Wire | Press release
IFF (NYSE: IFF) and SleepScore Labs introduce a groundbreaking scent solution to improve sleep quality, building on the partnership initiated in 2020 and leveraging IFF’s internal Science of Wellness program. The two companies will be demonstrating the new solution at the CES 2022 in Las Vegas - a scent that showed sleep improvement on an objective level in a SleepScore Labs study, including faster time to fall asleep, less time spent awake during the night, longer sleep duration, and improved sleep efficiency.
“IFF has always been a pioneer when it comes to creating scent solutions to improve people’s lives”, says Christophe de Villeplée, IFF’s Scent Division President. “The two first years of our partnership with SleepScore Labs were used by our perfumers and innovation teams to develop scents using our data science and SleepScore Labs biometric measures to improve sleep quality. The CES show will allow tech savvy visitors to discover our unique scent wellness solution and experience it firsthand”.
With 70% of the developed world impacted by poor sleep and the resulting adverse effects on overall health, the need to develop data-driven solutions is a call to action. IFF, an industry leader in food, beverage, scent, health and biosciences, and SleepScore Labs, the company behind a comprehensive suite of data-backed sleep solutions, leverage their combined expertise with a science-based, biometrically measured scent solution to support improved sleep.
The two organizations have collaborated to produce in-context biometrically tested scents. The studies utilize SleepScore’s non-contact measurement technology to extract respiratory signal and body movements, to not only determine sleep-wake cycles but also specific sleep stages, including Light, Deep, and REM. Their technology has been validated using polysomnography (PSG), the gold standard for objective sleep measurement.
”Billions of people are constantly searching for solutions to help them sleep better but most consumer solutions have little or no hard scientific data on their performance,” said Colin Lawlor, CEO of SleepScore Labs. “We are tremendously proud to work with IFF in leveraging the best data and science to bring real products which can be easily used in homes around the world to help people truly sleep better. Duly tested.”
To learn more about the IFF and SleepScore Labs scent sleep solutions, please see the companies’ video, IFFxSleepScore .
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .
About SleepScore Labs
We’re the sleep science and improvement company changing the world by improving sleep, based on science and leading-edge technology. SleepScore Labs was founded in 2016 by a team of sleep experts from companies, institutions and organizations such as ResMed, Apple, Philips, and Harvard. Together, we enable leading companies and organizations to strengthen their health and wellness offerings, proven through better sleep. After studying over 85 million hours of sleep for over a decade, we created the world’s most comprehensive suite of services which help consumers improve their sleep and companies to improve their offerings in the space
© 2021 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.
iff.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220102005018/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ Publishes 2026 ESG Progress Report, Highlighting Action Across Climate, People, Communities, and Responsible AI2.11.2026 12:45:00 CET | Press release
Report details NIQ’s continued focus on responsible business, including its first climate risk assessment, expanded employee development and more than 100,000 volunteer hours NIQ (NYSE: NIQ), a leading consumer intelligence company, today released its 2026 Environmental, Social and Governance (ESG) Progress Report, detailing the company’s progress on key ESG priorities throughout 2025. The report covers NIQ’s efforts across environmental responsibility, its people and communities, data integrity, and responsible AI. Key highlights from 2025 include:Strengthened its approach to climate risk and environmental measurement: NIQ conducted its first climate risk assessment aligned with Task Force on Climate-related Financial Disclosures (TCFD) recommendations, tracked Scope 1, 2 and 3 emissions under the GHG Protocol, and externally verified its carbon footprint. Invested in associate development, engagement and well-being: Internal mobility increased to 35%, up from 30%, while performance r
Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer2.11.2026 12:42:00 CET | Press release
In pMMR/MSS colon cancer, neoadjuvant BOT+BAL met the trial’s primary endpoint with a 36% major pathologic response rate, including 29% pathologic complete response, within an overall 71% pathologic response rate after one BOT dose and two BAL dosesNo patients treated with BOT+BAL had their cancer return, with median follow-up of 19.2 months in MSS disease and 16.7 months in MSI-H disease; 12-month event-free survival was 100% in both combination cohorts.Independent, multicenter UNICORN findings reinforce the NEST peer-reviewed neoadjuvant evidence supporting Agenus’ planned Phase 3 ROBBIN trial in curative-intent MSS/pMMR colon cancer Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of results from the investigator-sponsored, multicenter Phase 2 UNICORN trial evaluating short-course preoperative, or neoadjuvant, botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, alone or in combination with ba
New Joint Survey from Compass Pathways and the Depression and Bipolar Support Alliance Reveals the Lived Burden of Treatment-Resistant Depression on Patients and Caregivers2.11.2026 12:30:00 CET | Press release
New survey findings reveal the extent of unmet need for people living with treatment-resistant depression (TRD) and its impact on families, relationships and the ability to participate fully in everyday life Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, in partnership with the Depression and Bipolar Support Alliance (DBSA), today released a new report summarizing findings from a national survey of people living with TRD (n=261) and caregivers (n=73) on the self-reported realities of living with a condition that can profoundly affect daily life, revealing the burden of prolonged depressive episodes without meaningful relief. The survey findings demonstrate the impact of TRD across various aspects of everyday life, with many patients reporting years spent cycling through treatments without significant improvement while the condition takes a toll on their hope, identity, relationships and ab
Qorium Becomes Reyva as Cultivated Leather Company Moves Towards Commercial Scale2.11.2026 11:00:00 CET | Press release
New identity signals the company’s evolution into a standalone material brand for luxury and automotive markets Reyva develops real leather by cultivating bovine collagen from a small sample of animal cells. The new brand brings together advanced biotechnology, leather expertise and a clearer luxury proposition. The company’s team, technology, partnerships and commercial ambition continue under the new name. Qorium, the company that develops cultivated real leather, today announces that it is becoming Reyva. The new name and identity mark its next stage: moving from a pioneering technology business towards a global material brand built for the exacting standards of the luxury leather sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261102661351/en/ Reyva creates beautiful, high-performing real leather. By cultivating leather in uniform sheets, we can move beyond the natural limits of traditional hides, with greater con
Ant International Research Highlights How Readable AI Memories Can Unlock More Personalised, Privacy-conscious Consumer Experiences2.11.2026 09:52:00 CET | Press release
Human sales and customer representatives have institutional memories to serve clients: their preferences and choices. How can we build a memory mechanism for AI services to create similarly personalised experiences? Ant International’s research on this subject recently received the Senior Area Chair (SAC) Highlight Award from the Best Paper Committee at EMNLP 2026, a leading global AI conference. Why do we need “readable AI memory”? In this paper titled 'Text as a universal interface for transferable personalisation', we look into one fact: until now, AI memory of a user has usually been generated and stored as dense numerical code only the original system can interpret. Two long-standing problems with that: First, today's user profiles are "black boxes" — opaque code locked inside a single app, so activity in one service teaches nothing to another, and every product has to re-learn you from scratch. Second, profiles are welded to the model that created them, so they don't transfer whe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom